Rabbit Recombinant Monoclonal MTOR antibody. Suitable for WB, IHC-P and reacts with Mouse, Rat, Human samples. Cited in 123 publications.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9% PBS, 0.05% BSA
IP | Flow Cyt | WB | IHC-P | ICC/IF | |
---|---|---|---|---|---|
Human | Not recommended | Not recommended | Tested | Tested | Not recommended |
Mouse | Not recommended | Not recommended | Tested | Tested | Not recommended |
Rat | Not recommended | Not recommended | Tested | Tested | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info 1/10000 | Notes - |
Species Rat | Dilution info 1/10000 | Notes - |
Species Human | Dilution info 1/10000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info - | Notes Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Species Rat | Dilution info - | Notes Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Species Human | Dilution info - | Notes Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Human | Dilution info - | Notes - |
Select an associated product type
Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals (PubMed:12087098, PubMed:12150925, PubMed:12150926, PubMed:12231510, PubMed:12718876, PubMed:14651849, PubMed:15268862, PubMed:15467718, PubMed:15545625, PubMed:15718470, PubMed:18497260, PubMed:18762023, PubMed:18925875, PubMed:20516213, PubMed:20537536, PubMed:21659604, PubMed:23429703, PubMed:23429704, PubMed:25799227, PubMed:26018084, PubMed:29150432, PubMed:29236692, PubMed:31112131, PubMed:31601708, PubMed:32561715, PubMed:34519269, PubMed:37751742). MTOR directly or indirectly regulates the phosphorylation of at least 800 proteins (PubMed:15268862, PubMed:15467718, PubMed:17517883, PubMed:18372248, PubMed:18497260, PubMed:18925875, PubMed:20516213, PubMed:21576368, PubMed:21659604, PubMed:23429704, PubMed:29236692, PubMed:37751742). Functions as part of 2 structurally and functionally distinct signaling complexes mTORC1 and mTORC2 (mTOR complex 1 and 2) (PubMed:15268862, PubMed:15467718, PubMed:18497260, PubMed:18925875, PubMed:20516213, PubMed:21576368, PubMed:21659604, PubMed:23429704). In response to nutrients, growth factors or amino acids, mTORC1 is recruited to the lysosome membrane and promotes protein, lipid and nucleotide synthesis by phosphorylating key regulators of mRNA translation and ribosome synthesis (PubMed:12087098, PubMed:12150925, PubMed:12150926, PubMed:12231510, PubMed:12718876, PubMed:14651849, PubMed:15268862, PubMed:15467718, PubMed:15545625, PubMed:15718470, PubMed:18497260, PubMed:18762023, PubMed:18925875, PubMed:20516213, PubMed:20537536, PubMed:21659604, PubMed:23429703, PubMed:23429704, PubMed:25799227, PubMed:26018084, PubMed:29150432, PubMed:29236692, PubMed:31112131, PubMed:34519269). This includes phosphorylation of EIF4EBP1 and release of its inhibition toward the elongation initiation factor 4E (eiF4E) (PubMed:24403073, PubMed:29236692). Moreover, phosphorylates and activates RPS6KB1 and RPS6KB2 that promote protein synthesis by modulating the activity of their downstream targets including ribosomal protein S6, eukaryotic translation initiation factor EIF4B, and the inhibitor of translation initiation PDCD4 (PubMed:12087098, PubMed:12150925, PubMed:18925875, PubMed:29150432, PubMed:29236692). Stimulates the pyrimidine biosynthesis pathway, both by acute regulation through RPS6KB1-mediated phosphorylation of the biosynthetic enzyme CAD, and delayed regulation, through transcriptional enhancement of the pentose phosphate pathway which produces 5-phosphoribosyl-1-pyrophosphate (PRPP), an allosteric activator of CAD at a later step in synthesis, this function is dependent on the mTORC1 complex (PubMed:23429703, PubMed:23429704). Regulates ribosome synthesis by activating RNA polymerase III-dependent transcription through phosphorylation and inhibition of MAF1 an RNA polymerase III-repressor (PubMed:20516213). Activates dormant ribosomes by mediating phosphorylation of SERBP1, leading to SERBP1 inactivation and reactivation of translation (PubMed:36691768). In parallel to protein synthesis, also regulates lipid synthesis through SREBF1/SREBP1 and LPIN1 (PubMed:23426360). To maintain energy homeostasis mTORC1 may also regulate mitochondrial biogenesis through regulation of PPARGC1A (By similarity). In the same time, mTORC1 inhibits catabolic pathways: negatively regulates autophagy through phosphorylation of ULK1 (PubMed:32561715). Under nutrient sufficiency, phosphorylates ULK1 at 'Ser-758', disrupting the interaction with AMPK and preventing activation of ULK1 (PubMed:32561715). Also prevents autophagy through phosphorylation of the autophagy inhibitor DAP (PubMed:20537536). Also prevents autophagy by phosphorylating RUBCNL/Pacer under nutrient-rich conditions (PubMed:30704899). Prevents autophagy by mediating phosphorylation of AMBRA1, thereby inhibiting AMBRA1 ability to mediate ubiquitination of ULK1 and interaction between AMBRA1 and PPP2CA (PubMed:23524951, PubMed:25438055). mTORC1 exerts a feedback control on upstream growth factor signaling that includes phosphorylation and activation of GRB10 a INSR-dependent signaling suppressor (PubMed:21659604). Among other potential targets mTORC1 may phosphorylate CLIP1 and regulate microtubules (PubMed:12231510). The mTORC1 complex is inhibited in response to starvation and amino acid depletion (PubMed:12150925, PubMed:12150926, PubMed:24403073, PubMed:31695197). The non-canonical mTORC1 complex, which acts independently of RHEB, specifically mediates phosphorylation of MiT/TFE factors MITF, TFEB and TFE3 in the presence of nutrients, promoting their cytosolic retention and inactivation (PubMed:22343943, PubMed:22576015, PubMed:22692423, PubMed:24448649, PubMed:32612235, PubMed:36608670, PubMed:36697823). Upon starvation or lysosomal stress, inhibition of mTORC1 induces dephosphorylation and nuclear translocation of TFEB and TFE3, promoting their transcription factor activity (PubMed:22343943, PubMed:22576015, PubMed:22692423, PubMed:24448649, PubMed:32612235, PubMed:36608670). The mTORC1 complex regulates pyroptosis in macrophages by promoting GSDMD oligomerization (PubMed:34289345). MTOR phosphorylates RPTOR which in turn inhibits mTORC1 (By similarity). As part of the mTORC2 complex MTOR may regulate other cellular processes including survival and organization of the cytoskeleton (PubMed:15268862, PubMed:15467718). mTORC2 plays a critical role in the phosphorylation at 'Ser-473' of AKT1, a pro-survival effector of phosphoinositide 3-kinase, facilitating its activation by PDK1 (PubMed:15718470). mTORC2 may regulate the actin cytoskeleton, through phosphorylation of PRKCA, PXN and activation of the Rho-type guanine nucleotide exchange factors RHOA and RAC1A or RAC1B (PubMed:15268862). mTORC2 also regulates the phosphorylation of SGK1 at 'Ser-422' (PubMed:18925875). Regulates osteoclastogenesis by adjusting the expression of CEBPB isoforms (By similarity). Plays an important regulatory role in the circadian clock function; regulates period length and rhythm amplitude of the suprachiasmatic nucleus (SCN) and liver clocks (By similarity).
FRAP, FRAP1, FRAP2, RAFT1, RAPT1, MTOR, Serine/threonine-protein kinase mTOR, FK506-binding protein 12-rapamycin complex-associated protein 1, FKBP12-rapamycin complex-associated protein, Mammalian target of rapamycin, Mechanistic target of rapamycin, Rapamycin and FKBP12 target 1, Rapamycin target protein 1, mTOR
Rabbit Recombinant Monoclonal MTOR antibody. Suitable for WB, IHC-P and reacts with Mouse, Rat, Human samples. Cited in 123 publications.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9% PBS, 0.05% BSA
Expression levels of the target protein vary with sample type and some optimisation may be required.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
The mammalian target of rapamycin commonly known as mTOR is a serine/threonine kinase known for its role in cellular growth and metabolism. It has a molecular weight of approximately 289 kDa. mTOR is expressed in various tissues throughout the body including muscle adipose tissue and the brain. The protein functions as a central regulator of cell proliferation protein synthesis and nutrient signaling. Often researchers utilize mTOR ELISA or mTOR western blot (mTOR WB) methods and mTOR antibodies to study its expression and activity in various biological contexts.
MTOR integrates signals from nutrients growth factors and cellular energy status to maintain cellular homeostasis. It forms part of two distinct complexes mTORC1 and mTORC2 which differ in their component proteins and downstream effects. mTORC1 primarily responds to amino acids and regulates protein synthesis through phosphorylation of key substrates like S6K1. On the other hand mTORC2 is important for maintaining cytoskeletal integrity and cell survival highlighting the protein's importance in diverse cellular processes.
MTOR plays a pivotal role in the PI3K/AKT/mTOR pathway which governs cell growth proliferation and survival. It also has implications in the regulation of the AMPK pathway which senses cellular energy levels. Through these pathways mTOR interacts with proteins such as AKT and TSC2. The phospho-mTOR specifically the S2448 phospho-mTOR serves as an important functional marker in these signaling cascades linking extracellular signals to downstream cellular responses.
MTOR has connections to cancer and neurodegenerative diseases. Its dysregulation often leads to uncontrolled cellular proliferation a hallmark of many cancers. Conditions such as tuberous sclerosis can occur due to mutations in proteins like TSC1 and TSC2 that regulate mTOR activity. In Alzheimer's disease mTOR's role in autophagy and protein synthesis becomes significant as imbalance may contribute to disease progression. Understanding these connections highlights the potential of targeting mTOR pathways therapeutically.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
All lanes: Western blot - Anti-mTOR antibody [EPR390(N)] (ab134903) at 1/10000 dilution
Lane 1: Wild-type HEK293T whole cell lysate at 20 µg
Lane 2: MTOR knockout HEK293T whole cell lysate at 20 µg
Lane 3: K562 whole cell lysate at 20 µg
Predicted band size: 289 kDa
ab134903 was shown to react with mTOR in wild-type HEK-293T cells. Loss of signal was observed when knockout cell line Human MTOR knockout HEK-293T cell line ab255411 (knockout cell lysate Human MTOR knockout HEK-293T cell lysate ab263789) was used. Wild-type and mTOR knockout samples were subjected to SDS-PAGE. ab134903 and Anti-Vinculin antibody [VIN-54] (Anti-Vinculin antibody [VIN-54] ab130007) were incubated overnight at 4°C at 1 in 10000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-mTOR antibody [EPR390(N)] (ab134903) at 1/10000 dilution
Lane 1: Wild-type HEK-293 cell lysate at 20 µg
Lane 2: MTOR knockout HEK-293 cell lysate at 20 µg
Lane 2: Western blot - Human MTOR knockout HEK-293T cell line (Human MTOR knockout HEK-293T cell line ab255411)
Lane 3: Wild-type HEK-293T cell lysate at 20 µg
Lane 4: MTOR knockout HEK-293T cell lysate at 20 µg
All lanes: Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) at 1/20000 dilution
Predicted band size: 289 kDa
Observed band size: 124 kDa, 289 kDa
Blocking buffer and concentration 5% NFDM/TBST
Diluting buffer and concentration 5% NFDM/TBST
Exposure time:
Lane 1 to 5: 80 seconds
Lane 6 to 13: 180 seconds
This antibody detects non-specific bands. It doesn't detect the target band in some mouse and rat tissues.
All lanes: Western blot - Anti-mTOR antibody [EPR390(N)] (ab134903) at 1/1000 dilution
Lane 1: MCF7 (Human breast adenocarcinoma epithelial cell) whole cell lysates at 20 µg
Lane 2: HepG2 (Human hepatocellular carcinoma epithelial cell) whole cell lysates at 20 µg
Lane 3: Human brain lysates at 20 µg
Lane 4: Mouse brain lysates at 20 µg
Lane 5: Rat brain lysates at 20 µg
Lane 6: Human liver lysates at 20 µg
Lane 7: Mouse liver lysates at 20 µg
Lane 8: Human heart lysates at 20 µg
Lane 9: Mouse heart lysates at 20 µg
Lane 10: Rat heart lysates at 20 µg
Lane 11: Human kidney lysates at 20 µg
Lane 12: Mouse kidney lysates at 20 µg
Lane 13: Rat kidney lysates at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Predicted band size: 289 kDa
Observed band size: 290 kDa
All lanes: Western blot - Anti-mTOR antibody [EPR390(N)] (ab134903) at 1/10000 dilution
Lane 1: HeLa cell lysate at 10 µg
Lane 2: K562 cell lysate at 10 µg
Lane 3: Raji cell lysate at 10 µg
Lane 4: HepG2 cell lysate at 10 µg
Lane 5: 293T cell lysate at 10 µg
All lanes: HRP-conjugated goat anti-rabbit polyclonal IgG at 1/2000 dilution
Predicted band size: 289 kDa
Observed band size: 289 kDa
Immunohistochemical analysis of paraffin-embedded Mouse colon tissue labeling mTOR with ab134903 at 1/1000 (2.015 µg/ml) dilution, followed by a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (Rabbit specific IHC polymer detection kit HRP/DAB ab209101).
Positive staining on mouse colon. The section was incubated with ab134903 for 30mins at room temperature.
The immunostaining was performed on a Leica Biosystems BOND® RX instrument
Counterstained with hematoxylin.
Secondary antibody only control: Secondary antibody is a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (Rabbit specific IHC polymer detection kit HRP/DAB ab209101).
Heat mediated antigen retrieval was performed with Tris-EDTA buffer (pH 9.0, Epitope Retrieval Solution2) for 20 mins
Immunohistochemical analysis of paraffin-embedded A: Wild-type 293T (human embryonic kidney epithelial cell) cell pellet/B: MTOR knockout HEK293T cell pellet labeling mTOR with ab134903 at 1/1000 (2.015 µg/ml) dilution, followed by a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (Rabbit specific IHC polymer detection kit HRP/DAB ab209101).
Positive staining on (A) wild-type 293T cell pellet, no staining on (B) MTOR knockout HEK293T cell pellet. The section was incubated with ab134903 for 30mins at room temperature.
The immunostaining was performed on a Leica Biosystems BOND® RX instrument
Counterstained with hematoxylin.
Secondary antibody only control: Secondary antibody is a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (Rabbit specific IHC polymer detection kit HRP/DAB ab209101).
Heat mediated antigen retrieval was performed with Tris-EDTA buffer (pH 9.0, Epitope Retrieval Solution2) for 20 mins
Immunohistochemical analysis of paraffin-embedded Rat colon tissue labeling mTOR with ab134903 at 1/1000 (2.015 µg/ml) dilution, followed by a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (Rabbit specific IHC polymer detection kit HRP/DAB ab209101).
Positive staining on rat colon. The section was incubated with ab134903 for 30mins at room temperature.
The immunostaining was performed on a Leica Biosystems BOND® RX instrument
Counterstained with hematoxylin.
Secondary antibody only control: Secondary antibody is a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (Rabbit specific IHC polymer detection kit HRP/DAB ab209101).
Heat mediated antigen retrieval was performed with Tris-EDTA buffer (pH 9.0, Epitope Retrieval Solution2) for 20 mins
Immunohistochemical analysis of paraffin-embedded Human colon carcinoma tissue labeling mTOR with ab134903 at 1/1000 (2.015 µg/ml) dilution, followed by a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (Rabbit specific IHC polymer detection kit HRP/DAB ab209101).
Positive staining on human colon carcinoma. The section was incubated with ab134903 for 30 mins at room temperature.
The immunostaining was performed on a Leica Biosystems BOND® RX instrument
Counterstained with hematoxylin.
Secondary antibody only control: Secondary antibody is a ready to use Rabbit specific IHC polymer detection kit HRP/DAB (Rabbit specific IHC polymer detection kit HRP/DAB ab209101).
Heat mediated antigen retrieval was performed with Tris-EDTA buffer (pH 9.0, Epitope Retrieval Solution2) for 20 mins
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com